Takeda Pharmaceutical's (TAK) Takeda Canada said Monday that Health Canada has provided market authorization for Fruzaqla for the treatment of certain adult patients with metastatic colorectal cancer.
The authorization is based on data from two phase 3 trials in which Fruzaqla plus best supportive care showed "significant improvements in overall survival," with corresponding improvements in progression free survival, compared with placebo, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.